ABIONYX Pharma Announces the Reinitiation of Coverage of Its Stock by TPICAP Midcap
04 Juli 2022 - 5:46PM
Business Wire
Regulatory News:
ABIONYX Pharma (FR0012616852 - ABNX - PEA PME eligible)
(Paris:ABNX), a new generation biotech company
dedicated to the discovery and development of innovative therapies
for patients, announces the reinitiation of coverage of its stock
by TPICAP Midcap with a study entitled “Scaling Up”, giving a buy
recommendation with a target price of €8.10 per share.
The complete study can be found on the Company's website, in the
"Investors" section, "Analyst Research".
Next financial press release:
Cash position and activity update for Q2 2022, August 18,
2022
About ABIONYX Pharma
ABIONYX Pharma is a new generation biotech company that aims to
contribute to health through innovative therapies in indications
where there is no effective or existing treatment, even the rarest
ones. Thanks to its partners in research, medicine,
biopharmaceuticals and shareholding, the company innovates on a
daily basis to propose drugs for the treatment of renal and
ophthalmological diseases, or new HDL vectors used for targeted
drug delivery.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20220704005292/en/
NewCap Investor relations Louis-Victor Delouvrier Nicolas
Fossiez abionyx@newcap.eu +33 (0)1 44 71 98 53
NewCap Media relations Arthur Rouillé abionyx@newcap.eu
+33 (0)1 44 71 94 94
Abionyx Pharma (EU:ABNX)
Historical Stock Chart
Von Mär 2024 bis Apr 2024
Abionyx Pharma (EU:ABNX)
Historical Stock Chart
Von Apr 2023 bis Apr 2024
